Endothelial heparan sulfate proteoglycan (HSPG)

Endothelial cell surface components mediating TFPI release are primarily composed of heparan sulfate proteoglycans (HSPGs), such as glypican-1 and syndecans, which serve as the physiological anchors for Tissue Factor Pathway Inhibitor (TFPI) on the vascular wall (PubMed: 15507107). TFPI is a critical endogenous anticoagulant that inhibits the initiation of the extrinsic coagulation pathway by targeting the tissue factor-factor VIIa complex and factor Xa (PubMed: 8418358). Under normal physiological conditions, a significant pool of TFPI remains sequestered on the endothelial surface through electrostatic interactions between its positively charged C-terminus and the negatively charged glycosaminoglycan chains of HSPGs (PubMed: 11069127). Pharmacological agents, most notably unfractionated heparin and low molecular weight heparins, possess a higher affinity for these binding sites and competitively displace TFPI into the systemic circulation (PubMed: 1915436). This rapid increase in plasma TFPI concentration contributes significantly to the immediate antithrombotic effect of heparin therapy in clinical practice. Dysregulation of these surface components or the TFPI release mechanism is associated with various thrombotic disorders, cardiovascular diseases, and inflammatory states like sepsis (PubMed: 10449715).

Other names

Endothelial TFPI binding sitesHeparan sulfate proteoglycanGlypican-1SyndecanEndothelial cell surface components mediating TFPI releaseCell surface TFPI anchors

Competitive displacement of Tissue Factor Pathway Inhibitor (TFPI) from endothelial heparan sulfate proteoglycans into the systemic circulation, enhancing the inhibition of Factor Xa and the Tissue Factor-Factor VIIa complex.